Academic Journal
Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience
| العنوان: | Primary breast double-hit lymphoma management and outcomes: a real-world multicentre experience |
|---|---|
| المؤلفون: | Tingting Zhang, Yuanfeng Zhang, Hairong Fei, Xue Shi, Liang Wang, Peijun Wang, Jie Yu, Yuyan Shen, Sizhou Feng |
| المصدر: | Cancer Cell International, Vol 21, Iss 1, Pp 1-13 (2021) |
| بيانات النشر: | BMC, 2021. |
| سنة النشر: | 2021 |
| المجموعة: | LCC:Neoplasms. Tumors. Oncology. Including cancer and carcinogens LCC:Cytology |
| مصطلحات موضوعية: | Primary breast lymphoma, Double-hit lymphoma, High-grade B-cell lymphomas, Therapy, Relapse, Prognosis, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282, Cytology, QH573-671 |
| الوصف: | Abstract Background Primary breast double-hit lymphoma (PB-DHL) is a rare, highly aggressive malignancy that poses challenges regarding accurate diagnosis and selecting optimal treatment regimens. Methods We retrospectively reviewed 48 cases of patients diagnosed with PB-DHL in six academic centres between June 2014 and June 2020 in China. Study-specific data were recorded, including treatment options, therapeutic evaluation, prognostic factors and relapse patterns, and the overall survival (OS) and progression-free survival (PFS) were evaluated. Results In total, 48 patients were enrolled, with 14 patients treated with DA-EPOCH-R/MA (rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, alternating with high-dose methotrexate and cytarabine), 18 patients treated with DA-EPOCH-R (rituximab, dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin), and 16 patients treated with R-HyperCVAD (rituximab, hyperfractionated cyclophosphamide, vincristine, doxorubicin, dexamethasone, alternating with cytarabine plus methotrexate). The overall 5-year OS and PFS rates were 41.7% (95% confidence interval [CI], 27.6–56.8%) and 37.5% (95% CI, 24.0–52.6%), respectively. Of the three treatment regimens, the 5-year OS was higher in DA-EPOCH-R/MA group than in the DA-EPOCH-R or R-HyperCVAD subgroups (57.1% vs. 38.9% vs. 31.3%; P = 0.016), as was the 5-year PFS (50.0% vs. 38.9% vs. 25.0%; P = 0.035). Autologous stem cell transplantation (ASCT) prolonged the OS and PFS compared with non-ASCT patients (5-year OS: 72.2% vs. 23.3%; P |
| نوع الوثيقة: | article |
| وصف الملف: | electronic resource |
| اللغة: | English |
| تدمد: | 1475-2867 |
| Relation: | https://doaj.org/toc/1475-2867 |
| DOI: | 10.1186/s12935-021-02198-y |
| URL الوصول: | https://doaj.org/article/63b3292dcb904455802f9aef4cab9ec1 |
| رقم الانضمام: | edsdoj.63b3292dcb904455802f9aef4cab9ec1 |
| قاعدة البيانات: | Directory of Open Access Journals |
Full Text Finder | تدمد: | 14752867 |
|---|---|
| DOI: | 10.1186/s12935-021-02198-y |